Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QRH-882260 Peptide Imaging in the Bile Duct
NCT03438435Phase 1Completed
- Start
- Apr 2019
- Primary completion
- Aug 2020
- Modality
- Recombinant Proteins and Enzymes, Small Molecules, Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QRH-882260 in cholangiocarcinoma (CCA). Primary endpoint: Treatment-related Adverse Events at 30 months. Started Apr 2019; status: completed.
02
Drugs
QRH-882260
03
Conditions
cholangiocarcinoma (CCA)
Beyond the preview
Go deeper on NCT03438435.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03438435.